Idecabtagene vicleucel (Abecma)

From - A Hematology Oncology Wiki
Jump to navigation Jump to search

Mechanism of action

Anti-BCMA CAR T-cells.

Diseases for which it is used

History of changes in FDA indication

  • 3/26/2021: Approved for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. (Approval based on KarMMa)

Patient Drug Information

Also known as

  • Code name: bb2121
  • Generic name: ide-cel
  • Brand name: Abecma